AVDL
Price
$15.33
Change
-$0.26 (-1.67%)
Updated
Sep 25 closing price
Capitalization
1.49B
40 days until earnings call
COLL
Price
$34.65
Change
-$0.51 (-1.45%)
Updated
Sep 25 closing price
Capitalization
1.09B
41 days until earnings call
Interact to see
Advertisement

AVDL vs COLL

Header iconAVDL vs COLL Comparison
Open Charts AVDL vs COLLBanner chart's image
Avadel Pharmaceuticals
Price$15.33
Change-$0.26 (-1.67%)
Volume$1.05M
Capitalization1.49B
Collegium Pharmaceutical
Price$34.65
Change-$0.51 (-1.45%)
Volume$649.77K
Capitalization1.09B
AVDL vs COLL Comparison Chart in %
Loading...
AVDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVDL vs. COLL commentary
Sep 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVDL is a StrongBuy and COLL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 26, 2025
Stock price -- (AVDL: $15.33 vs. COLL: $34.65)
Brand notoriety: AVDL: Notable vs. COLL: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AVDL: 78% vs. COLL: 153%
Market capitalization -- AVDL: $1.49B vs. COLL: $1.09B
AVDL [@Pharmaceuticals: Generic] is valued at $1.49B. COLL’s [@Pharmaceuticals: Generic] market capitalization is $1.09B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVDL’s FA Score shows that 0 FA rating(s) are green whileCOLL’s FA Score has 1 green FA rating(s).

  • AVDL’s FA Score: 0 green, 5 red.
  • COLL’s FA Score: 1 green, 4 red.
According to our system of comparison, COLL is a better buy in the long-term than AVDL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVDL’s TA Score shows that 2 TA indicator(s) are bullish while COLL’s TA Score has 3 bullish TA indicator(s).

  • AVDL’s TA Score: 2 bullish, 5 bearish.
  • COLL’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, both AVDL and COLL are a bad buy in the short-term.

Price Growth

AVDL (@Pharmaceuticals: Generic) experienced а -5.55% price change this week, while COLL (@Pharmaceuticals: Generic) price change was -4.18% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.88%. For the same industry, the average monthly price growth was +23.85%, and the average quarterly price growth was +67.10%.

Reported Earning Dates

AVDL is expected to report earnings on Nov 05, 2025.

COLL is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AVDL($1.49B) has a higher market cap than COLL($1.09B). AVDL YTD gains are higher at: 45.861 vs. COLL (20.942). COLL has higher annual earnings (EBITDA): 347M vs. AVDL (7.87M). COLL has more cash in the bank: 222M vs. AVDL (81.5M). AVDL has less debt than COLL: AVDL (2.73M) vs COLL (829M). COLL has higher revenues than AVDL: COLL (707M) vs AVDL (221M).
AVDLCOLLAVDL / COLL
Capitalization1.49B1.09B136%
EBITDA7.87M347M2%
Gain YTD45.86120.942219%
P/E RatioN/A32.69-
Revenue221M707M31%
Total Cash81.5M222M37%
Total Debt2.73M829M0%
FUNDAMENTALS RATINGS
AVDL vs COLL: Fundamental Ratings
AVDL
COLL
OUTLOOK RATING
1..100
7068
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
67
Overvalued
PROFIT vs RISK RATING
1..100
5746
SMR RATING
1..100
9352
PRICE GROWTH RATING
1..100
3855
P/E GROWTH RATING
1..100
427
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

COLL's Valuation (67) in the Pharmaceuticals Other industry is in the same range as AVDL (82) in the Medical Specialties industry. This means that COLL’s stock grew similarly to AVDL’s over the last 12 months.

COLL's Profit vs Risk Rating (46) in the Pharmaceuticals Other industry is in the same range as AVDL (57) in the Medical Specialties industry. This means that COLL’s stock grew similarly to AVDL’s over the last 12 months.

COLL's SMR Rating (52) in the Pharmaceuticals Other industry is somewhat better than the same rating for AVDL (93) in the Medical Specialties industry. This means that COLL’s stock grew somewhat faster than AVDL’s over the last 12 months.

AVDL's Price Growth Rating (38) in the Medical Specialties industry is in the same range as COLL (55) in the Pharmaceuticals Other industry. This means that AVDL’s stock grew similarly to COLL’s over the last 12 months.

COLL's P/E Growth Rating (7) in the Pharmaceuticals Other industry is somewhat better than the same rating for AVDL (42) in the Medical Specialties industry. This means that COLL’s stock grew somewhat faster than AVDL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVDLCOLL
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
64%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
65%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
67%
Advances
ODDS (%)
Bullish Trend 9 days ago
85%
Bullish Trend 24 days ago
71%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 4 days ago
65%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
71%
Aroon
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
72%
View a ticker or compare two or three
Interact to see
Advertisement
AVDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HWNIX14.86N/A
N/A
Hotchkis & Wiley International Value I
JCVIX25.56N/A
N/A
JHancock Classic Value I
MSFKX20.10N/A
N/A
MFS Total Return R6
PFSQX26.44N/A
N/A
PGIM Jennison Financial Services R6
TEMVX10.10N/A
N/A
Nuveen Emerging Markets Eq W

AVDL and

Correlation & Price change

A.I.dvisor tells us that AVDL and RMTI have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AVDL and RMTI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVDL
1D Price
Change %
AVDL100%
-1.67%
RMTI - AVDL
32%
Poorly correlated
-3.17%
ELAN - AVDL
31%
Poorly correlated
+0.91%
RDY - AVDL
27%
Poorly correlated
-1.94%
EBS - AVDL
27%
Poorly correlated
+5.43%
COLL - AVDL
27%
Poorly correlated
-1.45%
More

COLL and

Correlation & Price change

A.I.dvisor indicates that over the last year, COLL has been loosely correlated with AMPH. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if COLL jumps, then AMPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To COLL
1D Price
Change %
COLL100%
-1.45%
AMPH - COLL
40%
Loosely correlated
-1.90%
AMRX - COLL
39%
Loosely correlated
-1.13%
VTRS - COLL
38%
Loosely correlated
-2.27%
ALKS - COLL
36%
Loosely correlated
-2.45%
SNDL - COLL
33%
Loosely correlated
-4.28%
More